J&J accepts $4B Carlyle offer for diagnostics unit (Update)

In this Tuesday, July 30, 2013, file photo, large banners hang in an atrium at the headquarters of Johnson & Johnson in New Brunswick, N.J. Johnson & Johnson has accepted an offer of about $4 billion from the private equity firm The Carlyle Group to buy its Ortho-Clinical Diagnostics business the company said Monday, March 31, 2014, that the deal for the blood-testing unit should close by mid-year. (AP Photo/Mel Evans, File)

Johnson & Johnson has accepted an offer of about $4 billion from the private equity firm The Carlyle Group to buy its Ortho-Clinical Diagnostics business.

J&J said Monday that the deal for the blood-testing unit should close by mid-year.

The health care giant had said in January that Washington, D.C.-based Carlyle Group had offered $4.15 billion for the business, and that it would talk to works councils and trade unions representing its employees before making a decision.

The Ortho-Clinical business serves hospitals, testing laboratories and blood banks. It supplies equipment and chemicals to screen donated blood for HIV, hepatitis C and other serious diseases. It also makes technology for advanced testing of blood to diagnose health conditions and to monitor medication effects.

Ortho Clinical Diagnostics is based in New Jersey and employs more than 4,500 employees. It runs factories in Rochester, New York; Pompano Beach, Florida; and Pencoed, Wales.

J&J CEO Alex Gorsky had said last year the company was looking at strategic options for Ortho-Clinical Diagnostics, which doesn't meet the company's long-held strategy of focusing on businesses that rank first or second in their markets.

Shares of J&J rose 78 cents to $98.22 in afternoon trading Monday. They had climbed more than 6 percent so far this year through Friday's close.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Carlyle Group makes $4.15B offer for J&J business

Jan 16, 2014

Johnson & Johnson said Thursday that it's been offered $4.15 billion by The Carlyle Group for its Ortho-Clinical Diagnostics business, a year after J&J began reviewing strategic options for the blood-testing ...

Continental buying Veyance Technologies for $1.91B

Feb 10, 2014

German auto parts maker Continental says it is buying rubber and plastics maker Veyance Technologies Inc. from private equity firm The Carlyle Group for 1.4 billion euros ($1.91 billion).

Thermo Fisher to buy Life Technologies for $13.6B (Update)

Apr 15, 2013

Thermo Fisher Scientific Inc. has offered to pay about $13.6 billion to buy genetic testing equipment maker Life Technologies in a cash deal that will create a giant company serving research and specialty diagnostics.

Recommended for you

Cambodia bans 'virgin surgery' adverts

22 hours ago

The Cambodian government has ordered a hospital to stop advertising so-called virginity restoration procedures, saying it harms the "morality" of society.

What's happening with your donated specimen?

Jan 28, 2015

When donating blood, plasma, human tissue or any other bodily sample for medical research, most people might not think about how it's being used. But if you were told, would you care?

Amgen tops Street 4Q forecasts

Jan 27, 2015

Amgen Inc. cruised to a 27 percent jump in fourth-quarter profit and beat Wall Street expectations, due to higher sales of nearly all its medicines, tight cost controls and a tax benefit.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.